Incidence of Medication-Related Problems Following Pediatric Epilepsy Admissions

Jessica Kulawiak1, Joette Amundaray Miller1, Sara W Hovey1

  • 1Department of Pharmacy, Rush University Medical Center, Chicago, Illinois.

Pediatric Neurology
|February 27, 2023
PubMed

Insights

Pediatric epilepsy patients experienced fewer medication problems after discharge with education, but the difference was not statistically significant. Education alone may not be sufficient to reduce medication errors in this vulnerable population.

Area of Science:

  • Pediatric Neurology
  • Pharmacology
  • Patient Safety

Background:

  • Medication errors at hospital discharge affect 26-33% of pediatric patients.
  • Pediatric patients with epilepsy face heightened risks due to complex medication needs and frequent hospitalizations.

Purpose of the Study:

  • To determine the rate of medication problems in pediatric epilepsy patients post-discharge.
  • To assess the impact of discharge medication education on reducing these problems.

Main Methods:

  • Retrospective cohort study comparing a control group with a group receiving discharge medication education (2:1 ratio).
  • Medical records reviewed from discharge to outpatient follow-up for medication problems.
  • Primary outcome: difference in medication problem proportion; secondary outcomes: harm potential, readmissions.

Main Results:

  • Incidence of medication problems was 29.4% (control) vs. 24.1% (education), P=0.44.
  • Medication problems with harm potential were 54.2% (control) vs. 28.6% (education), P=0.131.
  • Most common issues involved dose or direction discrepancies.

Conclusions:

  • Discharge medication education showed a trend toward reducing medication problems and harm potential in pediatric epilepsy patients, but differences were not statistically significant.
  • Education alone may be insufficient to significantly impact medication error rates in this population, suggesting a need for multifaceted interventions.
Abstract

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
236
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
235
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
933
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
386
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
457